131 related articles for article (PubMed ID: 32750566)
1. Discovery of novel anti-angiogenesis agents. Part 11: Development of PROTACs based on active molecules with potency of promoting vascular normalization.
Shan Y; Si R; Wang J; Zhang Q; Li J; Ma Y; Zhang J
Eur J Med Chem; 2020 Nov; 205():112654. PubMed ID: 32750566
[TBL] [Abstract][Full Text] [Related]
2. A novel 2-aminobenzimidazole-based compound Jzu 17 exhibits anti-angiogenesis effects by targeting VEGFR-2 signalling.
Lien JC; Chung CL; Huang TF; Chang TC; Chen KC; Gao GY; Hsu MJ; Huang SW
Br J Pharmacol; 2019 Oct; 176(20):4034-4049. PubMed ID: 31368127
[TBL] [Abstract][Full Text] [Related]
3. Development of a highly-potent anti-angiogenic VEGF8-109 heterodimer by directed blocking of its VEGFR-2 binding site.
Ghavamipour F; Shahangian SS; Sajedi RH; Arab SS; Mansouri K; Aghamaali MR
FEBS J; 2014 Oct; 281(19):4479-94. PubMed ID: 25132001
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel anti-angiogenesis agents. Part 6: Multi-targeted RTK inhibitors.
Zhang L; Shan Y; Li C; Sun Y; Su P; Wang J; Li L; Pan X; Zhang J
Eur J Med Chem; 2017 Feb; 127():275-285. PubMed ID: 28068599
[TBL] [Abstract][Full Text] [Related]
5. Discovery and molecular docking of quinolyl-thienyl chalcones as anti-angiogenic agents targeting VEGFR-2 tyrosine kinase.
Rizvi SU; Siddiqui HL; Nisar M; Khan N; Khan I
Bioorg Med Chem Lett; 2012 Jan; 22(2):942-4. PubMed ID: 22200597
[TBL] [Abstract][Full Text] [Related]
6. Eriocalyxin B, a natural diterpenoid, inhibited VEGF-induced angiogenesis and diminished angiogenesis-dependent breast tumor growth by suppressing VEGFR-2 signaling.
Zhou X; Yue GG; Liu M; Zuo Z; Lee JK; Li M; Tsui SK; Fung KP; Sun H; Pu J; Lau CB
Oncotarget; 2016 Dec; 7(50):82820-82835. PubMed ID: 27756875
[TBL] [Abstract][Full Text] [Related]
7. Design and Synthesis of Novel Thiazolo[5,4-d]pyrimidine Derivatives as Potential Angiogenesis Inhibitors.
Xue WJ; Du JY; Deng YH; Yan ZH; Liu JP; Liu Y; Sun LP
Chem Biodivers; 2019 Aug; 16(8):e1900232. PubMed ID: 31287621
[TBL] [Abstract][Full Text] [Related]
8. Discovery of 6-Arylurea-2-arylbenzoxazole and 6-Arylurea-2-arylbenzimidazole Derivatives as Angiogenesis Inhibitors: Design, Synthesis and in vitro Biological Evaluation.
Zi M; Liu F; Wu D; Li K; Zhang D; Zhu C; Zhang Z; Li L; Zhang C; Xie M; Lin J; Zhang J; Jin Y
ChemMedChem; 2019 Jul; 14(13):1291-1302. PubMed ID: 31131561
[TBL] [Abstract][Full Text] [Related]
9. Pyrimidinylacetamide-based 2-pyridylureas as Angiogenesis Inhibitors: Design, Synthesis and Biological Evaluation.
Deng YH; Yan ZH; Liu JP; Liu Y; Sun LP
Arch Med Res; 2017 May; 48(4):333-342. PubMed ID: 28882321
[TBL] [Abstract][Full Text] [Related]
10. Gamabufotalin, a major derivative of bufadienolide, inhibits VEGF-induced angiogenesis by suppressing VEGFR-2 signaling pathway.
Tang N; Shi L; Yu Z; Dong P; Wang C; Huo X; Zhang B; Huang S; Deng S; Liu K; Ma T; Wang X; Wu L; Ma XC
Oncotarget; 2016 Jan; 7(3):3533-47. PubMed ID: 26657289
[TBL] [Abstract][Full Text] [Related]
11. Discovery of Dioxino[2,3-f]quinazoline derivative VEGFR-2 inhibitors exerting significant antipro-liferative activity in HUVECs and mice.
Fan H; Wei D; Zheng K; Qin X; Yang L; Yang Y; Duan Y; Xu Y; Hu L
Eur J Med Chem; 2019 Aug; 175():349-356. PubMed ID: 31096155
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, biological evaluation and dynamics simulation of indazole derivatives with antiangiogenic and antiproliferative anticancer activity.
Elsayed NMY; Serya RAT; Tolba MF; Ahmed M; Barakat K; Abou El Ella DA; Abouzid KAM
Bioorg Chem; 2019 Feb; 82():340-359. PubMed ID: 30428414
[TBL] [Abstract][Full Text] [Related]
13. Discovery of novel anti-angiogenesis agents. Part 7: Multitarget inhibitors of VEGFR-2, TIE-2 and EphB4.
Li C; Shan Y; Sun Y; Si R; Liang L; Pan X; Wang B; Zhang J
Eur J Med Chem; 2017 Dec; 141():506-518. PubMed ID: 29102175
[TBL] [Abstract][Full Text] [Related]
14. Cryptotanshinone inhibits VEGF-induced angiogenesis by targeting the VEGFR2 signaling pathway.
Xu X; Wu L; Zhou X; Zhou N; Zhuang Q; Yang J; Dai J; Wang H; Chen S; Mao W
Microvasc Res; 2017 May; 111():25-31. PubMed ID: 28040437
[TBL] [Abstract][Full Text] [Related]
15. Anti-angiogenic activity and mechanism of kaurane diterpenoids from Wedelia chinensis.
Huang W; Liang Y; Wang J; Li G; Wang G; Li Y; Chung HY
Phytomedicine; 2016 Mar; 23(3):283-92. PubMed ID: 26969382
[TBL] [Abstract][Full Text] [Related]
16. The natural compound codonolactone impairs tumor induced angiogenesis by downregulating BMP signaling in endothelial cells.
Wang S; Cai R; Ma J; Liu T; Ke X; Lu H; Fu J
Phytomedicine; 2015 Oct; 22(11):1017-26. PubMed ID: 26407944
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel PROTACs based on multi-targeted angiogenesis inhibitors.
Si R; Hai P; Zheng Y; Liu N; Wang J; Zhang Q; Li Y; Pan X; Zhang J
Bioorg Med Chem Lett; 2023 May; 87():129275. PubMed ID: 37030566
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and discovery of pyrazine-pyridine biheteroaryl as a novel series of potent vascular endothelial growth factor receptor-2 inhibitors.
Kuo GH; Wang A; Emanuel S; Deangelis A; Zhang R; Connolly PJ; Murray WV; Gruninger RH; Sechler J; Fuentes-Pesquera A; Johnson D; Middleton SA; Jolliffe L; Chen X
J Med Chem; 2005 Mar; 48(6):1886-900. PubMed ID: 15771433
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel anti-angiogenesis agents. Part 10: Multi-target inhibitors of VEGFR-2, Tie-2 and EphB4 incorporated with 1,2,3-triazol.
Pan X; Liang L; Si R; Wang J; Zhang Q; Zhou H; Zhang L; Zhang J
Eur J Med Chem; 2019 Feb; 163():1-9. PubMed ID: 30503935
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and in vitro and in vivo anti-angiogenesis study of a novel vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitor based on 1,2,3-triazole scaffold.
Wang DP; Liu KL; Li XY; Lu GQ; Xue WH; Qian XH; Mohamed O K; Meng FH
Eur J Med Chem; 2021 Feb; 211():113083. PubMed ID: 33340911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
